Key facts

Invented name
  • Zelboraf
  • Zelboraf
Active Substance
vemurafenib
Therapeutic area
Oncology
Decision number
P/0210/2016
PIP number
EMEA-000978-PIP01-10-M01
Pharmaceutical form(s)
Film-coated tablet
Condition(s) / indication(s)
Treatment of melanoma
Route(s) of administration
Oral use
Contact for public enquiries

Roche Registration Limited

Switzerland
Tel. +41 6168794 11
Fax +41 616879411
E-mail: info.paediatrics@roche.com

Decision type
PM: decision on the application for modification of an agreed PIP
Decision date

Decision

How useful do you find this page?